Navigation Links
Diagenode Releases Two New Epigenetic Monoclonal 5-hmC Antibodies for Quantifying Global Hydroxymethylation
Date:9/22/2010

LIEGE, Belgium, Sept. 22 /PRNewswire/ -- Diagenode announced today that it has released two additional 5-hmC antibodies to complement its original 5-hmC (rat) monoclonal antibody. The two new 5-hmC monoclonal antibody (mouse) and polyclonal antibody (rabbit) antibodies give researchers additional choices for enriching and analyzing 5-hmC in their methylation studies.

(Photo: http://photos.prnewswire.com/prnh/20100922/NY69887 )

(Photo: http://www.newscom.com/cgi-bin/prnh/20100922/NY69887 )

The importance of 5-hmC to the epigenetic field was highlighted in a recent Epigenie review: "A year after 5-hydroxymethylcytosine's (5-hmC) dramatic entrance into the epigenetics research scene, the research community has a long list of questions to ask about the 6th base. Investigations into 5-hmC were sidelined for most of the year due to the absence of methods to analyze it. Thankfully those helpless days are history as Diagenode just launched the first 5-hmC monoclonal antibody, an innovation that makes enriching and analyzing 5-hmC a reality." (www.epigenie.com, May 11, 2010) 

These latest additions make available the broadest range of validated methylation products to the research community. Prior to this, there were no other validated antibodies available in the market for routinely identifying 5-hmC and discriminating this base from 5-mC. Diagenode and collaborators have extended validation of the 5-hmC antibody from the standard Dot Blot and Immunofluorescence approaches to hMeDIP, and hMeDIP-Seq profiling.

What is truly exciting for researchers is they will now be able to perform Dual MeDIP Assays with multiple choices of 5-hmC antibodies (Diagenode's hMeDIP kit), first by utilizing the 5-hmC monoclonal or polyclonal antibody in hMeDIP, and then the Diagenode monoclonal 33D3 MeDIP Assay (Diagenode's MeDIP kit). This approach will allow researchers to profile both types of cytosine marks in one experiment.  

Diagenode was founded in 2003. Its research and development division is continually improving its technical knowledge of DNA methylation as evident in Diagenode's Methylated DNA Immunoprecipitation (MeDIP), Bi-Sulfite, Methyl binding domain (MBD) protein (also known as MethylCap) and the gold standard 33D3 5-methylcytosine antibody (5-mC) offerings.

About Diagenode

Diagenode is a multinational life science company that develops and commercializes innovative instruments and reagents for epigenetic research. Major product lines include; IP-Star ® Automation, Bioruptor® Sonication, epigenetic targeted antibodies & kits, and methylation. Founded in 2003 in Liege (Belgium), Diagenode has offices in Liege, Belgium and Denville, New Jersey.

www.Diagenode.com


'/>"/>
SOURCE Diagenode
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Health Robotics Releases Results of First 20 i.v.STATIONs Return On Investment (ROI) Studies in the USA and Canada
2. Promega Releases 2009 Corporate Sustainability Report
3. Arrowhead Releases New Report Assessing State of Personalized Medicine Market
4. Hayes, Inc. Releases Guide to BRCA1 and BRCA2 Genetic Testing
5. MD Bioproducts Releases a New Mouse T1/ST2 ELISA
6. Centrifuge Releases New Data Visualization Software
7. Sunlight Research(TM), Releases its Osiris Therapeutics Stem Cell Patent Report
8. VKernel Releases Optimization Pack 1.2
9. Datafarm Releases New Desktop-based Application for Multi-region Viewing of eCTD Submissions: Datafarm VUE
10. SCDM Releases Best Practices for Automated Data Cleaning
11. Signatec Releases PX1500-4, Its 4-Channel, 1.5 GHz Per Channel / 2-Channel, 3 GHz Per Channel PCI-Express Digitizer with Two Virtex-5 FPGAs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Brooklyn, NY (PRWEB) , ... June 24, 2016 , ... ... 15mm, machines such as the Cary 5000 and the 6000i models are higher end ... height is the height of the spectrophotometer’s light beam from the bottom of the ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
(Date:6/23/2016)... June, 23, 2016  The Biodesign Challenge (BDC), a ... ways to harness living systems and biotechnology, announced its ... in New York City . ... students, showcased projects at MoMA,s Celeste Bartos Theater during ... , MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
Breaking Biology Technology:
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
(Date:4/15/2016)... -- Research and Markets has announced the ...  report to their offering.  ,      ... gait biometrics market is expected to grow at ... Gait analysis generates multiple variables such ... compute factors that are not or cannot be ...
(Date:3/29/2016)... Florida , March 29, 2016 ... the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased ... in ink used in a variety of writing instruments, ... Buyers of originally created collectibles from athletes on LegacyXChange ... forensic analysis of the DNA. Bill ...
Breaking Biology News(10 mins):